FILING ANALYSIS · FRIDAY, NOVEMBER 13
Milestone Pharmaceuticals Inc. MIST — 8-K: Results of Operations and Financial Condition
neutral
Milestone Pharmaceuticals announced cost-efficiency measures to extend cash runway through AFib-RVR Phase 3 data, including a 30% reduction in operating expenses, and reported $1.0 million in net product revenue for Q3 2026, up 73% from Q2 2026. The company's cash and equivalents of $145.4 million are expected to provide operating runway into late 2028.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →